NexTel Medical Expands into Brain Repair Market with New Strategic Acquisition
New York, Wednesday, 5 August 2026.
NexTel Medical has agreed to acquire Xycota Biosciences, entering the neuro-restoration market with innovative therapies targeting untreated conditions like Frontotemporal Dementia and ALS.
Strategic Acquisition Announced
On Wednesday, August 5, 2026, NexTel Medical Corp. (OTCID: MAJI) executed a definitive Letter of Intent (LOI) to acquire 100% of Xycota Biosciences, LLC [1]. This strategic transaction aims to position NexTel at the forefront of the precision neuro-restoration sector by integrating Xycota’s proprietary exosome-delivered brain circuitry repair platform [1]. The deal represents a significant consolidation in biotechnology, offering potential advancements for neurodegenerative medical treatments and commercial applications [1].
The acquisition marks a defining milestone in NexTel Medical’s corporate development and growth trajectory, according to company statements released today [1]. By securing full ownership of Xycota, NexTel intends to leverage existing commercial infrastructure to accelerate the deployment of novel therapies [1]. This move underscores a broader trend of consolidation within the biotechnology sector as firms seek to diversify pipelines with high-potential assets [1].
Proprietary Neuro-Restoration Platform
Xycota’s lead therapeutic candidate, XYCO-01, utilizes proprietary fungal-derived exosome delivery systems to upregulate the BDNF-TrkB neuroplasticity signaling pathway [1]. This technology is designed to avoid first-pass liver metabolism and hallucinogenic receptor activation, addressing key safety concerns in CNS drug development [1]. The platform specifically targets the repair of brain circuitry, differentiating it from traditional symptom-management treatments [1].
The acquisition integrates Xycota’s technology with NexTel’s commercial infrastructure, with future pipeline expansion targets including Amyotrophic Lateral Sclerosis (ALS) and mild traumatic brain injury (mTBI) [1]. Engineering exosome-delivered neuroplasticity therapeutics allows for precise delivery mechanisms that bypass traditional biological barriers [1]. This technical capability is central to the value proposition presented to shareholders during the announcement [1].
Regulatory Pathway and Pipeline Expansion
Xycota has applied for FDA Orphan Drug Designation (ODD) for XYCO-01 to treat Frontotemporal Dementia (FTD), with issuance expected shortly [1]. The regulatory status is pending, but the designation targets conditions where no restorative therapies currently exist [1]. Achieving Orphan Drug Designation can provide significant market exclusivity and development incentives upon approval [1].
The strategic focus remains on neurodegenerative disorders such as Frontotemporal Dementia and ALS, which represent immense unmet clinical needs [1]. Future pipeline expansion targets also include mild traumatic brain injury, broadening the potential addressable market [1]. The integration of these assets aims to create a value-generative catalyst for shareholders through diversified risk and reward profiles [1].
Executive Commentary on Growth
Matthew Dwyer, President and Chief Executive Officer of NexTel Medical Corp., emphasized that combining Xycota’s breakthrough neuro-restoration architecture with NexTel’s commercial infrastructure creates an extraordinary opportunity [1]. Dr. Marvin S. Hausman, MD, Co-Founder and Chief Scientific Officer of Xycota, leads the pipeline with over 50 years of CNS drug development experience and 6 successful FDA New Drug Applications (NDAs) [1]. Their leadership is pivotal in navigating the complex regulatory and clinical landscape ahead [1].
Executive commentary highlights that Xycota’s cutting-edge exosome delivery platform addresses immense unmet clinical needs in Frontotemporal Dementia and ALS [1]. The collaboration seeks to merge scientific innovation with robust commercial execution to maximize patient impact [1]. Stakeholders anticipate that this alignment will drive long-term growth and therapeutic availability [1].